His primary scientific interests are in Multiple sclerosis, Internal medicine, Surgery, Central nervous system disease and Physical therapy. Carlo Pozzilli is interested in Expanded Disability Status Scale, which is a field of Multiple sclerosis. His Internal medicine research incorporates themes from Placebo and Cardiology.
Carlo Pozzilli interconnects Gastroenterology, Pregnancy, Obstetrics and Hazard ratio in the investigation of issues within Surgery. His research in Central nervous system disease intersects with topics in Corpus callosum, Neurology and Brain size. His Physical therapy research is multidisciplinary, relying on both Quality of life, Crossover study and Physical medicine and rehabilitation.
His main research concerns Multiple sclerosis, Internal medicine, Magnetic resonance imaging, Physical therapy and Expanded Disability Status Scale. His Multiple sclerosis study combines topics in areas such as Surgery, Central nervous system disease and Neurology. His studies examine the connections between Internal medicine and genetics, as well as such issues in Placebo, with regards to Randomized controlled trial.
His studies deal with areas such as Lesion, Pathology, Brain damage and Nuclear medicine as well as Magnetic resonance imaging. His Physical therapy study incorporates themes from Quality of life, Disease, Physical medicine and rehabilitation and Clinical trial. His work deals with themes such as Cohort and Hazard ratio, which intersect with Expanded Disability Status Scale.
The scientist’s investigation covers issues in Multiple sclerosis, Internal medicine, Alemtuzumab, In patient and Expanded Disability Status Scale. His research integrates issues of Neurology, Neuroradiology and Pediatrics in his study of Multiple sclerosis. The study incorporates disciplines such as Dimethyl fumarate and Oncology in addition to Internal medicine.
In general Alemtuzumab study, his work on MS-II often relates to the realm of Clinical neurology, thereby connecting several areas of interest. Carlo Pozzilli combines subjects such as Cardiology, Fractional anisotropy, Tolerability, Treatment response and Cohort with his study of Expanded Disability Status Scale. His work in Treatment response addresses issues such as Disease management, which are connected to fields such as Management of multiple sclerosis, Magnetic resonance imaging and Intensive care medicine.
His primary areas of study are Multiple sclerosis, Internal medicine, Expanded Disability Status Scale, Cohort and Relapsing remitting. His Management of multiple sclerosis study in the realm of Multiple sclerosis interacts with subjects such as In patient. His Internal medicine study integrates concerns from other disciplines, such as Dimethyl fumarate, Alemtuzumab and Teriflunomide.
His Expanded Disability Status Scale research incorporates elements of Prolonged release, Tolerability, Adverse effect and Hazard ratio. His Cohort research includes elements of Proportional hazards model and Clinically isolated syndrome. In his study, which falls under the umbrella issue of Relapsing remitting, Early disease, T2 lesions, MEDA and Interferon beta is strongly linked to Disease activity.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Defining the clinical course of multiple sclerosis: The 2013 revisions
Fred D. Lublin;Stephen C. Reingold;Jeffrey A. Cohen;Gary R. Cutter.
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
A. Novotna;J. Mares;S. Ratcliffe;I. Novakova.
European Journal of Neurology (2011)
Diffusion-weighted imaging tractography-based parcellation of the human lateral premotor cortex identifies dorsal and ventral subregions with anatomical and functional specializations.
Valentina Tomassini;Saad Jbabdi;Johannes C. Klein;Timothy E. J. Behrens.
The Journal of Neuroscience (2007)
Multiple sclerosis in childhood: clinical features of 149 cases.
A. Ghezzi;V. Deplano;J. Faroni;MG Grasso.
Multiple Sclerosis Journal (1997)
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring
Ludwig Kappos;David Bates;Gilles Edan;Mefkûre Eraksoy.
Lancet Neurology (2007)
fMRI evidence of brain reorganization during attention and memory tasks in multiple sclerosis.
Caterina Mainero;Francesca Caramia;Carlo Pozzilli;Angela Pisani.
Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome
E Millefiorini;C Gasperini;C Pozzilli;F D'Andrea.
Journal of Neurology (1997)
The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis
Pd Molyneux;L Kappos;C Polman;C Pozzilli.
Progressing Neurological Deficit Secondary to Acute Ischemic Stroke: A Study on Predictability, Pathogenesis, and Prognosis
Danilo Toni;Marco Fiorelli;Mara Gentile;Stefano Bastianello.
JAMA Neurology (1995)
Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis
P. S. Sørensen;F. Deisenhammer;P. Duda;R. Hohlfeld.
European Journal of Neurology (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: